 <h1>Erlotinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of erlotinib include:</b> infection, conjunctivitis, diarrhea, dyspnea, keratoconjunctivitis, nausea, pruritus, skin rash, stomatitis, anorexia, and xeroderma.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to erlotinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, erlotinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking erlotinib:</p><p>
<i>More common</i>
</p><ul>
<li>Burning, tingling, numbness or pain in the hands, arms, feet, or legs</li>
<li>cough or hoarseness</li>
<li>diarrhea (severe)</li>
<li>difficult or labored breathing</li>
<li>fever or chills</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>rash (severe)</li>
<li>sensation of pins and needles</li>
<li>stabbing chest pain</li>
<li>tightness in the chest</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloody or black, tarry stools</li>
<li>blurred vision</li>
<li>chest pain or discomfort</li>
<li>constipation</li>
<li>convulsions (seizures)</li>
<li>eye irritation or redness</li>
<li>inability to speak</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>severe stomach pain</li>
<li>slurred speech</li>
<li>sudden, severe chest pain</li>
<li>sudden, severe headache</li>
<li>sudden, severe weakness in the arm or leg on one side of the body</li>
<li>sweating</li>
<li>vision changes</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloody nose</li>
<li>burning feeling in the chest or stomach</li>
<li>burning upper abdominal or stomach pain</li>
<li>confusion</li>
<li>dark-colored urine</li>
<li>darkening of the skin</li>
<li>decreased urine output</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>lethargy</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>mood changes</li>
<li>muscle pain or stiffness</li>
<li>muscle twitching</li>
<li>nausea or vomiting</li>
<li>rapid weight gain</li>
<li>red skin lesions, often with a purple center</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomach pain, continuing</li>
<li>stupor</li>
<li>swelling of the face, ankles, or hands</li>
<li>tenderness in the stomach area</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of erlotinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>blemishes on the skin</li>
<li>bloated or full feeling</li>
<li>bone pain</li>
<li>burning, dry, or itching eyes</li>
<li>diarrhea (mild)</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>dry eyes</li>
<li>dry skin</li>
<li>excess air or gas in the stomach or intestines</li>
<li>excessive tearing</li>
<li>fear</li>
<li>feeling sad or empty</li>
<li>feeling unusually cold</li>
<li>hair loss</li>
<li>headache</li>
<li>heartburn</li>
<li>indigestion</li>
<li>irritability</li>
<li>itching skin</li>
<li>joint pain</li>
<li>loss of interest or pleasure</li>
<li>nervousness</li>
<li>passing gas</li>
<li>pimples</li>
<li>rash, mild</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>shivering</li>
<li>stomach discomfort, upset, or pain</li>
<li>swelling</li>
<li>swelling or inflammation of the mouth</li>
<li>swollen joints</li>
<li>thinning of the hair</li>
<li>tiredness</li>
<li>trouble or inability to sleep</li>
<li>trouble with concentrating</li>
<li>weight loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Loosening of the fingernails</li>
<li>redness or soreness around the fingernails</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Brittle and loose nails</li>
<li>discharge, excessive tearing</li>
<li>increased hair growth, especially on the face</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to erlotinib: oral tablet</i></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (41%), cough (33%)</p>
<p><b>Common</b> (1% to 10%): Epistaxis, interstitial lung disease<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (75%), alopecia (14%), pruritus (13%), dry skin (12%)</p>
<p><b>Common</b> (1% to 10%): Acne, dermatitis acneiform, folliculitis, skin fissures, paronychia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperpigmentation, hirsutism, brittle/loose nails, eyebrow changes</p>
<p><b>Rare</b> (less than 0.1%): Palmar plantar erythrodysesthesia syndrome, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (54%), nausea (33%), vomiting (23%), stomatitis (22%), dyspepsia (17%), flatulence (13%), abdominal pain (11%)</p>
<p><b>Common</b> (1% to 10%): GI bleeding</p>
<p><b>Uncommon</b> (0.1% to 1%): GI perforations<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Liver function test abnormalities (including elevated ALT, AST, bilirubin)</p>
<p><b>Rare</b> (less than 0.1%): Hepatic failure and hepatorenal syndrome (including fatalities)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (24%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Keratoconjunctivitis sicca (12%), conjunctivitis (12%)</p>
<p><b>Common</b> (1% to 10%): Keratitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Eyelash changes</p>
<p><b>Rare</b> (less than 0.1%): Corneal ulcerations or perforations</p>
<p><b>Postmarketing reports</b>: Uveitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal insufficiency</p>
<p><b>Uncommon</b> (0.1% to 1%): Nephritis, proteinuria</p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (73%), pyrexia (36%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Myocardial infarction/ischemia, cerebrovascular accident</p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (53%), weight decreased (39%)</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Rigors (12%)</p>
<p><b>Postmarketing reports</b>: Myopathy, including rhabdomyolysis, in combination with statin therapy</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (15%), neuropathy (13%)</p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (19%)</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Liu V,  White DA,  Zakowski MF, et al. "Pulmonary toxicity associated with erlotinib." Chest 132 (2007): 1042-4</p><p id="ref_2">2. "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA. </p><p id="ref_3">3. Marquez G,  Herrera-Acosta E,  Vidal I,  Galvany L,  Iglesias M,  Umbert P "A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva)." Int J Dermatol 48 (2009): 97-8</p><p id="ref_4">4. PharmaLive "Skin rash actually signifies better outcomes for pancreatic and lung cancer patients. Available from: URL: http://pharmalive.com/news/Print.cfm?articleid=456520"   ([2007 Jul 3]):</p><p id="ref_5">5. Cuetara MS,  Aguilar A,  Martin L,  Aspiroz C,  Del Palacio A "Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis." Br J Dermatol 155 (2006): 477-9</p><p id="ref_6">6. Pellegrinotti M,  Fimognari FL,  Franco A,  Repetto L,  Pastorelli R "Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer." Ann Pharmacother 43 (2009): 542-5</p><p id="ref_7">7. Lee SM,  Buchler T,  Joseph T,  Lai C "Bilateral eardrum perforation after long-term treatment with erlotinib." J Clin Oncol 26 (2008): 2582-4</p></div>
<div class="more-resources" id="moreResources">
<h2>More about erlotinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>42 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Erlotinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Tarceva</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
<li>Pancreatic Cancer</li>
<li>Renal Cell Carcinoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to erlotinib: oral tablet</i></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (41%), cough (33%)</p><p><b>Common</b> (1% to 10%): Epistaxis, interstitial lung disease<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (75%), alopecia (14%), pruritus (13%), dry skin (12%)</p><p><b>Common</b> (1% to 10%): Acne, dermatitis acneiform, folliculitis, skin fissures, paronychia</p><p><b>Uncommon</b> (0.1% to 1%): Hyperpigmentation, hirsutism, brittle/loose nails, eyebrow changes</p><p><b>Rare</b> (less than 0.1%): Palmar plantar erythrodysesthesia syndrome, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (54%), nausea (33%), vomiting (23%), stomatitis (22%), dyspepsia (17%), flatulence (13%), abdominal pain (11%)</p><p><b>Common</b> (1% to 10%): GI bleeding</p><p><b>Uncommon</b> (0.1% to 1%): GI perforations<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Liver function test abnormalities (including elevated ALT, AST, bilirubin)</p><p><b>Rare</b> (less than 0.1%): Hepatic failure and hepatorenal syndrome (including fatalities)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (24%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Keratoconjunctivitis sicca (12%), conjunctivitis (12%)</p><p><b>Common</b> (1% to 10%): Keratitis</p><p><b>Uncommon</b> (0.1% to 1%): Eyelash changes</p><p><b>Rare</b> (less than 0.1%): Corneal ulcerations or perforations</p><p><b>Postmarketing reports</b>: Uveitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal insufficiency</p><p><b>Uncommon</b> (0.1% to 1%): Nephritis, proteinuria</p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (73%), pyrexia (36%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Myocardial infarction/ischemia, cerebrovascular accident</p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (53%), weight decreased (39%)</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Rigors (12%)</p><p><b>Postmarketing reports</b>: Myopathy, including rhabdomyolysis, in combination with statin therapy</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (15%), neuropathy (13%)</p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (19%)</p><p id="ref_1">1. Liu V,  White DA,  Zakowski MF, et al. "Pulmonary toxicity associated with erlotinib." Chest 132 (2007): 1042-4</p><p id="ref_2">2. "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA. </p><p id="ref_3">3. Marquez G,  Herrera-Acosta E,  Vidal I,  Galvany L,  Iglesias M,  Umbert P "A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva)." Int J Dermatol 48 (2009): 97-8</p><p id="ref_4">4. PharmaLive "Skin rash actually signifies better outcomes for pancreatic and lung cancer patients. Available from: URL: http://pharmalive.com/news/Print.cfm?articleid=456520"   ([2007 Jul 3]):</p><p id="ref_5">5. Cuetara MS,  Aguilar A,  Martin L,  Aspiroz C,  Del Palacio A "Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis." Br J Dermatol 155 (2006): 477-9</p><p id="ref_6">6. Pellegrinotti M,  Fimognari FL,  Franco A,  Repetto L,  Pastorelli R "Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer." Ann Pharmacother 43 (2009): 542-5</p><p id="ref_7">7. Lee SM,  Buchler T,  Joseph T,  Lai C "Bilateral eardrum perforation after long-term treatment with erlotinib." J Clin Oncol 26 (2008): 2582-4</p><h2>More about erlotinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>42 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Erlotinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
<li>Pancreatic Cancer</li>
<li>Renal Cell Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>